Do outcomes after kidney transplantation differ for black patients in England versus New York State? A comparative, population-cohort analysis by Tahir, Sanna et al.
 
 
Do outcomes after kidney transplantation differ for
black patients in England versus New York State? A
comparative, population-cohort analysis
Tahir, Sanna; Gillott, Holly; Jackson-spence, Francesca; Nath, Jay; Mytton, Jemma; Evison,
Felicity; Sharif, Adnan
DOI:
10.1136/bmjopen-2016-014069
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Tahir, S, Gillott, H, Jackson-spence, F, Nath, J, Mytton, J, Evison, F & Sharif, A 2017, 'Do outcomes after kidney
transplantation differ for black patients in England versus New York State? A comparative, population-cohort
analysis', BMJ open, vol. 7, no. 5, e014069. https://doi.org/10.1136/bmjopen-2016-014069
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
 1Tahir S, et al. BMJ Open 2017;7:e014069. doi:10.1136/bmjopen-2016-014069
ABSTRACT
Objectives Inferior outcomes for black kidney transplant 
recipients in the USA may not be generalisable elsewhere. 
In this population cohort analysis, we compared outcomes 
for black kidney transplant patients in England versus New 
York State.
Design Retrospective, comparative, population cohort 
study utilising administrative data registries.
Settings and participants English data were derived from 
Hospital Episode Statistics, while New York State data were 
derived from Statewide Planning and Research Cooperative 
System. All adults receiving their first kidney-alone allograft 
between 2003 and 2013 were eligible for inclusion.
Measures The primary outcome measure was mortality post 
kidney transplantation (including inhospital death, 30-day 
mortality and 1-year mortality). Secondary outcome measures 
included postoperative admission length of stay, risk of 
rehospitalisation, development of cardiac events, stroke, 
cancer or fracture and finally transplant rejection/failure. 
Cox proportional hazards regression was used to investigate 
relationship between ethnicity, country and outcome.
Results Black patients comprised 6.5% of the English 
cohort (n=1215/18 493) and 23.0% of the New York State 
cohort (n=2660/11 602). Compared with New York State, 
black kidney transplant recipients in England were more 
likely younger, male, living-donor kidney recipients and had 
dissimilar medical comorbidities. Inpatient mortality was 
not statistically different, but death within 30 days, 1 year or 
kidney transplant rejection/failure was lower among black 
patients in England versus black patients in New York State. 
In adjusted regression analysis, with black ethnicity the 
reference group, white patients had reduced risk for 30-
day mortality (OR 0.62 (95% CI 0.44 to 0.86)) and 1-year 
mortality (OR 0.79 (95% CI 0.63 to 0.99)) in New York State 
but no difference was observed in England. Compared with 
England, black kidney transplant patients in New York State 
had increased HR for kidney transplant rejection rejection/
failure by median follow-up (HR 2.15, 95% CI 1.91 to 2.43).
Conclusions Outcomes after kidney transplantation for 
black patients may not be translatable between countries.
INTRODUCTION
Black patients are significantly more likely 
to develop end-stage kidney disease (ESKD), 
which is likely secondary to increased risk 
of chronic kidney disease progressing to 
kidney failure.1 Adjusted incident rates for 
black patients (or African-Americans) in the 
United States Renal Data System (USRDS) in 
2014 (latest available data) was the highest 
for any ethnicity group, with a ESKD inci-
dence rate ratio versus white patients of 3.1.2 
Even in countries with a lower incidence of 
ESKD than the USA like the UK, there is a 
disproportionate number of black patients 
with ESKD undergoing renal replacement 
therapy compared with the general popula-
tion.3 Therefore, strategies to optimise care 
for black patients with ESKD remains of crit-
ical importance.
While kidney transplantation is recognised 
as the preferred modality of renal replacement 
therapy for patients with ESKD, disparate 
post-transplant outcomes are reported for 
black recipients of a kidney allograft. For 
example, black kidney transplant patients in 
the USA have previously been shown to have 
worse kidney allograft survival compared 
with white recipients,4 although recent 
analyses suggest reduced disparity (but still 
not equality) in kidney allograft outcomes 
between black and white patients in the 
contemporary era in the USA.5 However, this 
is not generalisable across North America as 
Canadian black transplant patients appear 
to have similar kidney allograft survival and 
improved mortality compared with Canadian 
white kidney transplant patients.6 Mortality 
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differences after kidney transplantation between the USA 
and Canada are well recognised, with magnification of risk 
for death observed in black Americans versus Canadians.7 
In a European setting, Pallet and colleagues have shown 
no difference in outcomes for black versus white patients 
after kidney transplantation in France,8 and no mortality 
difference is observed between black and white patients 
in the UK.9 10 Therefore, inferior mortality observed for 
black kidney transplant patients widely attributed to the 
USA may be country specific, thus making interpretation 
of such data difficult for other population cohorts like 
the UK.
No comparative analysis has ever been conducted to 
specifically compare post-transplant outcomes for black 
kidney transplant patients between countries across 
distinct geographical regions like the UK and the USA. 
This is of interest as healthcare systems differ significantly 
between the two countries, with the possibility that black 
people in the UK may not share the same post-transplant 
outcomes observed in the USA. Therefore, it is unclear 
if the counselling of black kidney transplant candidates 
in one country can be adequately made utilising data 
translated from black patients in another country. The 
aim of this analysis was to undertake a comparative popu-
lation-based cohort analysis exploring outcomes after 
kidney transplantation for black patients in England 
versus New York State.
MATERIALS AND METHODS
Study population
We obtained data from every patient's first kidney-alone 
transplant procedure performed in England and New 
York State between 2003 and 2013, collecting patient 
demographics that included age, gender, donor type 
(living or deceased), transplant year, medical comorbid-
ities (based on International Classification of Disease, 
10th revision (ICD-10) codes) and ethnicity. English 
data were obtained from Hospital Episode Statistics,11 an 
administrative data warehouse containing admissions to 
all National Health Service (NHS) hospitals in England. 
It contains detailed records relating to individual patient 
treatments, with data extraction facilitated utilising 
codes on procedural classifications (Office of Population 
Censuses and Surveys Classification of Interventions and 
Procedures, fourth revision (OPCS-4))12 and medical 
classifications (WHO ICD-10).13 The comparative anal-
ysis with the USA was performed with contemporaneous 
New York State data and extracted from the Statewide 
Planning and Research Cooperative System (SPARCS), a 
comprehensive all-payer data reporting system collecting 
patient level data across New York State.14 The database 
collects information including patient demographics, 
diagnoses and procedures and charges for every inpa-
tient hospital admission, ambulatory surgical procedure, 
and emergency department admission. Individuals 
are assigned a unique, encrypted identification code, 
allowing for longitudinal analyses. Estimated reporting 
completeness obtained from SPARCS inpatient annual 
reports during the study period (2000–2011) ranged 
from 95% to 100%, with an average of more than 98%.
This study included all patients’ first kidney transplant 
procedures (OPCS-4 codes; M01(0–5,8,9)) performed in 
England and New York State between the years 2003–2013. 
With regards to outcome analysis, both Hospital Episode 
Statistics (HES) and SPARCS data sets have the limitation 
of only capturing deaths occurring in a hospital setting. 
To obtain the complete mortality list, the study cohort 
was cross-referenced with mortality data from the Office 
for National Statistics and New York State/New York City 
Vital Statistics, respectively, which collects information 
on all registered deaths in the UK and New York State, 
respectively. Death data were available from 1 January 
2013 up until 31 December 2014. Combining sources 
via this data linkage process creates a comprehensive 
data set with regards to mortality, which was the endpoint 
of interest in this analysis. In addition, we extracted data 
for kidney transplant rejection/failure (ICD-10: T861 or 
ICD-9: 99 681), which is derived from the administrative 
data and substituted for lack of data linkage to transplant 
registry records. Formal ethical approval was not required 
due to the pseudonymised nature of the data retrieved; 
data were linked by NHS Informatics utilising a special 
HES ID code and avoided any patient identifiable infor-
mation. Thus, the study was registered as an audit with 
University Hospitals Birmingham NHS Trust (audit iden-
tifier; CARMS-12578).
Data inclusion
We extracted data on all adult kidney allograft recipients’ 
first procedure between the dates of 1 January 2003 and 31 
December 2013, who underwent their kidney transplant 
procedure in a transplant centre in either England or New 
York State. From our original cohorts of 21 371 and 12 373 
patients in England and New York States, respectively, we 
excluded from analysis 2582 and 771 patients from both 
data sets, respectively, as shown in online supplementary 
figure 1. Ethnicity status was missing in <5 cases (too small 
to identify), although anyone classified as unknown was 
included under ‘other’ for analysis. All patients were 
followed up until December 2014.
Outcomes
The primary outcome measure was all-cause mortality 
post kidney transplantation (including inhospital death, 
30-day mortality and 1-year mortality). In addition, we 
looked at various secondary outcome measures including 
postoperative admission length of stay, risk of re-hospital-
isation, development of cardiac events (ICD-10: I2(01234), 
ICD-9: 410,411,413,429), stroke (ICD-10: I6(0 12 3456), 
ICD-9: 430–436), cancer (ICD-10:C00-C99, ICD9: 
140–199) or fracture (ICD-10: S(0123456789)2, T02, T07, 
T10, T12, ICD-9: 800–829) and finally kidney transplant 
rejection/failure (ICD-10: T861, ICD-9: 99 681). Rehospi-
talisation was defined as whether a patient was readmitted 
to hospital as an emergency at any time postdischarge of 
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their transplant admission. All other secondary outcomes 
were captured with use of ICD-10 and ICD-9 codes (as 
defined above), at any time post-transplant.
Statistical analysis
Differences between groups were compared using χ2 
tests for categorical variables two-sample t-test for normal 
continuous variables or Mann-Whitney tests for all 
non-normal continuous variables. Multivariate logistic 
regression was used to measure 30-day and 12-month 
mortality. All patients were included in these models to 
see if there was a difference in mortality outcomes for 
the different ethnic groups, within the two populations. 
Variables included in the models were age, sex, admission 
method (emergency vs elective), number of emergency 
readmissions and ethnic group. Survival analyses were 
performed, combining all black patients in the two coun-
tries, for the outcome of graft failure/rejection (defined 
using ICD-10: T861 or ICD-9: 99681 at any time post-trans-
plant) using Cox’s proportional hazards model and the 
generation of Kaplan-Meier plots. The proportional 
hazard assumption was checked and satisfied by exam-
ination of the scaled Schoenfeld residual plots. Variables 
included in the Cox model were ethnicity, age, gender, 
donor type (living vs deceased), year of transplant, 
geography (England vs New York State) and selected 
medical comorbidities at the time of transplant (history 
of myocardial infarction, peripheral vascular disease, 
cerebrovascular disease, congestive cardiac failure and 
diabetes). Sensitivity analyses, stratified by ethnicity and 
donor type, were further conducted for both English and 
New York State. A p value less than 0.05 was considered 
statistically significant in the analysis. All statistical anal-
yses were conducted using Stata V.14.
RESULTS
Between 2003 and 2013, there were 21 371 patients 
in England and 12 373 patients in New York State who 
had their first kidney transplant. After exclusions due to 
missing age or sex, and those who had multiorgan trans-
plants, data were analysed for 18 493 and 11 602 patients 
between 2003 and 2013 from England and New York State, 
respectively, with median follow-up in England and New 
York State of 6.3 years and 5.5 years, respectively. Black 
patients comprised 6.5% of the English cohort (n=1215) 
and 23.0% of the New York State cohort (n=2660), 
forming the basis of all comparative analyses.
Baseline demographics
Table 1 compares demographics between black patients 
in England versus New York State. Black kidney allograft 
recipients in England versus New York State were found 
to be younger (46.1 vs 50.1, respectively, p<0.001), more 
likely to be male (61.2% vs 56.8%, respectively, p=0.011) 
and more likely to get living-donor kidneys (28.2% vs 
20.6%, respectively, p<0.001). We also observed black 
recipients in England versus New York State had less 
medical comorbidities listed at time of transplanta-
tion including diabetes (16.0% vs 27.9%, respectively, 
p<0.001), previous myocardial infarcts (2.1% vs 3.7%, 
respectively, p<0.001), strokes (1.2% vs 1.7%, respectively, 
Table 1 Baseline demographics of black kidney transplant recipients in England versus NYS between 2003 and 2013*
Total
England
(n=1215)
NYS
(n=2660) p Value
Age Mean±SD 46.3±12.4 50.1±13.5 <0.001*
Total length of stay Median±IQR 10±8–16 6±5–9 <0.001†
Post-transplant hospital stay Median±IQR 8±6–13 6±4–8 <0.001†
Sex, n (%) Male 743 (61.2) 1511 (56.8) 0.011‡
Female 472 (38.8) 1149 (43.2)
Type of donor, n (%) Living 343 (28.2) 548 (20.6) <0.001‡
Deceased 856 (70.5) 1555 (58.5)
Unknown 16 (1.3) 557 (20.9)
Medical comorbidities at time of 
transplantation, n (%)
Diabetes 194 (16.0) 741 (27.9) <0.001‡
Acute MI 25 (2.1) 99 (3.7)
Cerebrovascular disease 14 (1.2) 46 (1.7)
Congestive heart failure 22 (1.8) 220 (8.3)
Liver disease 6 (0.5) 16 (0.6)
Peptic ulcer 8 (0.7) 31 (1.2)
Peripheral vascular disease 13 (1.1) 83 (3.1)
 *t-Test.
†Mann-Whitney test. 
‡χ2 test.
NYS, New York State. 
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p<0.001) and congestive cardiac failure (1.8% vs 8.0%, 
respectively, p<0.001), suggesting a higher level of medical 
comorbidity listed at the time of kidney transplantation 
for black patients in New York State versus England.
Post-transplant outcomes
Table 2 demonstrates the difference in mortality 
outcomes comparing black kidney transplant patients in 
England versus New York State. While inpatient mortality 
was similar comparing black patients in England versus 
New York State (0.7% vs 1.4%, respectively, p=0.099), 
mortality was significantly lower among black patients 
in England versus New York State within 30 days (1.0% 
vs 2.3%, respectively, p=0.006) and 1 year (2.8% vs 6.5%, 
respectively, p<0.001)) after kidney transplantation.
There were significant differences in the post-trans-
plantation course for black kidney transplant patients 
in England versus New York State (see tables 1 and 2). 
Black patients in England versus New York State had 
longer postoperative inpatient stays (median 8 vs 6 days, 
p<0.001) and had a greater tendency to be readmitted 
within the first year post-transplant (64.36% vs 33.53%, 
p<0.001), but overall mean number of emergency rehos-
pitalisation episodes post-transplant by median follow-up 
was similar between the two cohorts (4.3 vs 4.0, respec-
tively, p=0.07). With regards to medical events occurring 
post kidney transplantation, black patients in England 
versus New York State were less likely to have cardiac 
events (6.0% vs 12.6%, respectively, p<0.001), but no 
difference was observed in episodes of cancer, strokes or 
fractures after kidney transplantation for black patients in 
England versus New York State.
Regression analysis
While our analyses revealed significant mortality differ-
ences between black patients in England versus New York 
State, we were keen to understand if black ethnicity itself 
was a risk factor for mortality in each population cohort. 
In a logistic regression model, accounting for variables 
associated with mortality after kidney transplantation 
(age, sex, admission method and number of emergency 
readmissions), we analysed whether black ethnicity was 
an independent predictor for death in England or New 
York State. With black ethnicity utilised as the reference 
group, table 3 displays the output from the logistic regres-
sion analysis and shows white kidney allograft recipients 
had reduced risk for 30-day mortality (OR 0.62 (95% CI 
0.44 to 0.86)) and 1-year mortality (OR 0.66 (95% CI 
0.55 to 0.81)) in New York State, but no difference was 
observed in England (30-day mortality: OR 0.81 (0.44 to 
1.49) and 1-year mortality: OR 0.94 (0.65 to 1.34). Addi-
tional sensitivity analyses exploring risk for mortality 
between both cohorts, stratified by ethnicity and donor 
type, were conducted and are shown in the online supple-
mentary material.
A significant difference was observed in unadjusted 
Kaplan-Meier plots of kidney transplant rejection/failure 
for black kidney transplant patients in England versus New 
York State (see figure 1). After adjustment for baseline 
variables, Cox regression analysis confirmed black kidney 
Table 2 Comparing 1 year and follow-up outcomes after kidney transplantation for black patients in England versus New York 
State between 2003 and 2014
Variable England, n (%) New York State, n (%) p Value
1-Year follow-up
Emergency readmission 782 (64.36) 892 (33.53) <0.001
Cardiac event 16 (1.32) 79 (2.97) 0.002
Stroke 12 (0.99) 23 (0.86) <0.001
Cancer 17 (1.40) 26 (0.98) 0.245
Fracture 5 (0.41) 18 (0.68) 0.319
Transplant rejection/failure 226 (18.6) 702 (26.4) <0.001
Any time post-transplant
Number of emergency readmissions (mean) 4.33 3.99 0.0697
Cardiac event 72 (5.93) 336 (12.63) <0.001
Stroke 47 (3.87) 125 (4.70) 0.224
Cancer 71 (5.84) 171 (6.43) 0.485
Fracture 36 (2.96) 84 (3.16) 0.745
Transplant rejection/failure 367 (30.2) 1590 (59.8) <0.001
Mortality
Inhospital death 9 (0.74) 36 (1.35) 0.099
30-day mortality 12 (0.99) 61 (2.29) 0.006
12-month mortality 34 (2.80) 173 (6.50) <0.001
Obtained using χ2 tests.
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transplant patients in New York State versus England had 
over the double the HR for kidney transplant rejection/
failure during follow-up (HR 2.15, 95% CI 1.91 to 2.43) (see 
table 4), which was identical to a similar analysis focusing 
only on white patients (see online supplementary table 1).
DISCUSSION
Our comparative analysis of two large population-based 
cohort data sets demonstrates that black kidney trans-
plant patients have different baseline characteristics and 
post-transplant outcomes in England compared with New 
York State. Most importantly, black patients in England 
have lower mortality than their New York State counter-
parts, where black ethnicity in the latter cohort was found 
to be independently associated with increased 30-day and 
1-year mortality. Our analysis, to our knowledge, is the 
first comparative study comparing black kidney allograft 
outcomes in contemporaneous population cohorts. Our 
study highlights significant differences between black 
kidney transplant patients in England versus New York 
State and suggests caution in translating outcomes for 
black transplant patients between different countries.
The strengths and weaknesses of this study must be appre-
ciated for the correct interpretation of our results. There 
are likely to be numerous confounders that have an impact 
on black mortality post kidney transplantation that we were 
unable to factor in (eg, smoking, lifestyle, sociocultural 
factors and dialysis vintage). It should be acknowledged 
that New York State data may not be completely representa-
tive of other states in the USA, and we are crudely inferring 
that data from New York State is broadly representative of 
the USA. Missing data (and misclassification bias) also have 
an implication on the analyses performed, and this limita-
tion is inherent with all epidemiological studies of this 
Figure 1 Unadjusted Kaplan-Meier curve of kidney transplant rejection/failure for black kidney transplant patients in England 
versus New York State (NYS) between 2003 and 2014 (log-rank test, p <0.001).
Table 3 Adjusted logistic regression analysis of kidney transplant mortality in both England and New York State by ethnicity 
between 2003 and 2014*
Ethnicity
England New York State
OR (95% CI) p Value* OR (95% CI) p Value*
30-Day mortality
Black 1 (baseline group) 1 (baseline group)
Other 1.48 (0.76 to 2.88) 0.246 0.79 (0.55 to 1.15) 0.214
White 0.81 (0.44 to 1.49) 0.491 0.62 (0.44 to 0.86) 0.005
1-Year mortality
Black 1 (baseline group) 1 (baseline group)
Other 1.27 (0.85 to 1.90) 0.234 0.79 (0.63 to 0.99) 0.064
White 0.94 (0.65 to 1.34) 0.728 0.66 (0.55 to 0.81) <0.001
*Adjusted for age, sex, admission method and number of emergency readmissions.
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type. Unfortunately, while the majority of data obtainable 
was matched between the two cohorts, we were unable to 
extract any information regarding socioeconomic depriva-
tion status or cause of death from the SPARCS data set. Our 
utilisation of the composite for kidney transplant rejection/
failure from administration records is an inferior surro-
gate compared with registry-derived data regarding kidney 
allograft rejection and graft failure. The ability to extract 
more data, and to link data sets to create more comprehen-
sive databases, allows the minimisation of confounding and 
provides a more robust platform from which to conduct 
meaningful epidemiological analysis. Further work in this 
area is clearly warranted and should be undertaken using 
more robust renal data including registry data from both 
the USA (eg, USRDS and Scientific Registry of Transplant 
Recipients) and the UK (eg, UK Transplant Registry and 
Renal Registry). Finally, mortality data are readily avail-
able and were the sole analytical endpoint of this analysis. 
However, absence of recorded death may not necessarily 
translate to assumption that a recipient remains alive (eg, 
lost to follow-up due to emigration).
Current literature suggests that black kidney trans-
plant patients in the USA have inferior kidney allograft 
survival compared with white recipients,4 and risk for 
death is magnified among black American versus Cana-
dian kidney transplant patients.7 Reassuringly, recently 
published work demonstrates significant improvement 
in post kidney transplant outcomes in the USA over the 
last two decades, more so for black versus white patients, 
leading to reduced disparity.5 This may be related to 
advances in immunosuppression and post-transplant 
management, possibly benefiting black kidney transplant 
patients more significantly who perhaps were more dispro-
portionately overburdened by immunological barriers in 
the past. While some disparity remained in their analysis 
in relation to significantly raised adjusted HRs for black 
patients and risk for graft loss in the contemporary 
setting, the vastly improved outcomes were encouraging 
for transplant clinicians to actively promote kidney trans-
plantation among black patients. Our analysis suggested 
worse kidney allograft outcomes since 2007 for all black 
kidney transplant recipients, which may be due to more 
high-risk kidney transplantation of medically complex or 
immunological difficult patients, but this requires further 
analysis with more transplant-specific data as it may simply 
reflect better administrative coding of kidney rejection/
failure since 2007.
By contrast, no mortality difference between black and 
white patients has been observed in the few limited publi-
cations within European transplant centres.8–10 Our data 
therefore support the inference from existing literature 
about disparate outcomes for black patients in the USA 
versus elsewhere and raises two important questions: (1) 
Why outcomes for black transplant patients in the USA 
remain inferior to white patients, and (2) Why black 
transplant patients in the USA have inferior outcomes 
in comparison with black patients outside of the USA. It 
could be argued that the Black population in England 
differs from the USA, but this is an insufficient expla-
nation as black people in Canada and the USA share 
geographical origins but still have dissimilar mortality 
outcomes.7 It is important to distinguish the signifi-
cant differences in baseline demographics between our 
two black cohorts. For example, medical comorbidities 
such as history of diabetes and atherosclerotic diseases 
were less common among black transplant recipients in 
England compared with New York State, suggesting a 
higher level of cardiovascular burden at baseline for the 
latter. This could explain the significantly increased risk 
for cardiac events within the first year after kidney trans-
plantation for black kidney transplant patients in New 
York State versus England. Due to the absence of cause of 
death from the SPARCS data, we were unable to ascertain 
the nature of deaths among black patients in New York 
State, but an increase in cardiac deaths would be a reason-
able assumption. However, baseline demographics alone 
cannot account for the significant difference in mortality.
Perhaps the most fundamental difference between 
countries is the infrastructure delivering and providing 
healthcare. Black kidney transplant patients in England 
have universal health coverage as part of the taxpay-
er-funded NHS. This ensures complete financial access 
to immunosuppressive medications and other aspects 
of care including allied medications (eg, antihyperten-
sive agents, glucose-lowering agents and lipid-lowering 
Table 4 Adjusted Cox regression analysis for transplant 
rejection/failure among black kidney transplant patients in 
England and NYS between 2003 and 2014
HR (95% CI) p Value
Age 1.00 (0.99 to 1.00) 0.171
Sex
Male 1 (baseline group)
Female 1.00 (0.91 to 1.09) 0.928
Type of donor
Alive 1 (baseline group)
Dead 1.37 (1.22 to 1.54) <0.001
Unknown 1.08 (0.92 to 1.27) 0.339
Diabetes 1.09 (0.98 to 1.20) 0.114
Acute MI 0.99 (0.84 to 1.17) 0.935
CVD 1.04 (0.87 to 1.24) 0.697
PVD 1.16 (0.98 to 1.37) 0.086
CHF 1.16 (1.04 to 1.30) 0.008
Year
Pre-2007 1 (baseline group)
Post-2007 1.30 (1.16 to 1.45) <0.001
Country
England 1 (baseline group)
NYS (USA) 2.15 (1.91 to 2.43) <0.001
CHF, congestive heart failure; CVD, cerebrovascular disease; MI, 
myocardial infarction; NYS, New York State.
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drugs) and long-term medical follow-up to support 
post-transplant care. Compared with the USA, countries 
such as England, Canada and France that demonstrate 
similar mortality outcomes after transplantation for black 
versus white patients share elements of universal health 
coverage,6 8–10 and this is an obvious factor to explain 
disparate mortality outcomes. This is also supported by 
our analysis also showing improved graft survival for white 
patients in England versus New York States, suggesting 
our analysis reflects better outcomes overall in England 
rather than any ethnicity effect. However, universal health 
coverage alone is unlikely to be the sole explanation 
for differing outcomes. Prospective clinical trials in the 
USA, which may attenuate the risk of any lack of access, 
still demonstrate poorer outcomes for black patients in 
subgroup analyses,15 suggesting health coverage alone 
does not fully explain poor outcomes. This is supported by 
evidence within the USA shown by Chakkera et al in their 
exploration of racial disparities using kidney transplant 
cohorts, which included patients receiving healthcare 
within versus outside the Department of Veterans Affairs 
(VA).16 The VA is the largest integrated managed health-
care system in the USA and provides comprehensive 
medical care to eligible veterans including coverage of 
prescription drugs. Perhaps surprisingly, the association 
of black ethnicity with poorer outcomes was consistent 
in non-VA versus VA users, with the latter associated with 
increased risk of graft loss (adjusted graft failure 1.31, 
95% CI 1.10 to 1.57) and death (adjusted mortality 1.10, 
95% CI 0.90 to 1.34). While noting adjusted mortality for 
VA users was not significantly raised in the analysis (likely 
due to a smaller cohort of 1646 VA users versus 77 715 
non-VA users), the adjusted risks for graft failure and 
death were almost identical between VA and non-VA users 
(1.31 and 1.31, respectively, for graft failure and 1.10 and 
1.11, respectively, for mortality).
This raises the question as to what underlies poor 
outcomes among black kidney transplant patients in the 
USA while acknowledging disparate outcomes appears 
to be narrowing between black and white patients' 
post kidney transplantation.5 Factors such as non-adher-
ence, which could be a surrogate for non-affordability of 
drugs in the USA, is a phenomenon that is common in 
transplantation cohorts everywhere (including countries 
with universal health coverage).17 There could be selec-
tion bias from poor access to transplantation for black 
people, which has been acknowledged in transplant 
centres across the world and has been comprehensively 
reviewed elsewhere.18 However, from the most up-to-date 
census reports, individuals of black ethnicity make up 
3.5% of the English population19 and 17.6% of the New 
York State population20 and black patients formed 6.5% 
and 23.0% of our transplant cohorts, respectively. While 
this suggests black patients are over-represented as kidney 
allograft recipients in both England and New York State, 
respectively, it must be remembered that ESKD is more 
prevalent in black communities, and therefore they are 
more likely to need renal replacement therapy. In should 
be noted that disparate post-transplant outcomes between 
Europe and the USA are not unique to kidney allograft 
recipients of black ethnicity alone. Gondos et al, analysing 
data from the United Network for Organ Sharing and 
the Collaborative Transplant Study, compared kidney 
transplant outcomes in the USA versus Europe, respec-
tively.21 Adjusted HRs for graft loss were higher in the 
USA compared with Europe and identifying the contrib-
uting factors to this disparity should be considered a 
high priority to improve the delivery of post-transplant 
care. Socioeconomic status, education and poverty are all 
likely to be important, and black transplant patients in 
the USA may be an inherent risk for higher mortality or 
have weaker social support networks or negative health 
behaviour that drives risk for adverse outcomes (such 
as smoking, alcohol consumption, sedentary lifestyle 
and poor diet).22–24 It is clear that our understanding 
of the social epidemiological impact on health inequal-
ities is limited,25 but deepening our understanding of 
these issues may further reduce the disparity in mortality 
outcomes seen in the USA for black kidney allograft 
recipients.
Our analysis should be interpreted in the context of 
the well-recognised observation of reduced risk for death 
for black versus white ESKD patients after commence-
ment of dialysis, and this phenomenon has been noted 
in both the USA2 and the UK.3 However, inferring that 
all black patients on dialysis have reduced risk for death 
on dialysis may be incorrect when interpreting large 
population cohorts in the context of competing factors. 
For example, Kucirka  et al conducted an observational 
cohort study of 1 330 007 incident end-stage renal disease 
patients in the USRDS and showed black patients have 
lower mortality on dialysis than white patients (adjusted 
HR 0.84; 95% CI 0.83 to 0.84; p<0.001).26 However, after 
stratification by age and treating kidney transplantation 
as a competing risk, black patients below the age of 50 
had significantly higher mortality than their white coun-
terparts on dialysis. Teasing out the differences that help 
explain our disparate mortality outcomes between black 
patients in England versus New York State will likely prove 
more challenging than just a simple explanation. Caution 
must also be exercised in the interpretation of epidemio-
logical data to ensure false inferences are not made from 
statistical analyses. For example, Yeates et al found black 
kidney transplant patients in Canada had significantly 
lower post-transplantation mortality compared with white 
patients (HR 0.49; 95% CI 0.28 to 0.88; p=0.02).6 This 
finding is surprising, and the only documented example 
of this observation, which requires corroboration before 
any legitimate interpretation, can be made. However, 
there are recognised steps that can be taken to reduce 
the risk of post-transplant mortality for black patients 
including greater use of living-kidney donors, which has 
been shown to improve outcomes and to reduce racial 
disparity of post-transplant outcomes.27
To conclude, this is the first comparative study exam-
ining mortality for black kidney transplant patients 
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between two different countries and found black kidney 
transplant patients in New York State have a greater 
hazard for death and kidney transplant failure/rejection 
compared with their black counterparts in England. Our 
results suggest that further work is essential to investigate 
poor outcomes for black patients after kidney transplan-
tation in the USA to aid our inadequate understanding of 
their social, environmental and/or biological pressures. 
While macro-level factors like universal health coverage 
may be an important factor contributing to post-trans-
plantation mortality and allograft loss for black patients, 
our study suggests additional micro-level factors are likely 
to be concomitantly important and are in need of deeper 
evaluation.
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